Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/06/2017 12/07/2017 12/08/2017 12/11/2017 12/12/2017 Date
314.66(c) 319.57(c) 325.77(c) 328.03(c) 327.75 Last
938 762 987 076 1 133 930 1 142 809 747 277 Volume
-1.63% +1.56% +1.94% +0.69% -0.09% Change
More quotes
Financials ($)
Sales 2017 12 033 M
EBIT 2017 6 342 M
Net income 2017 3 880 M
Debt 2017 3 226 M
Yield 2017 -
Sales 2018 12 624 M
EBIT 2018 6 812 M
Net income 2018 4 465 M
Debt 2018 1 233 M
Yield 2018 -
P/E ratio 2017 17,70
P/E ratio 2018 15,21
EV / Sales2017 6,03x
EV / Sales2018 5,59x
Capitalization 69 371 M
More Financials
Company
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for... 
Sector
Pharmaceuticals
Calendar
12/13 | 06:00pmPresentation
More about the company
Surperformance© ratings of Biogen
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN
12/07 BIOGEN : to Present at the Guggenheim 5th Annual Healthcare Conference
12/05DJRoche's Breast Cancer Drug Herceptin Faces Biosimilar Competition -Cinco Dias
12/04 BIOGEN : Appoints Mark Hernon as SVP, Chief Information Officer
11/28 BIOGEN : Today's Research Reports on Stocks to Watch: Biogen and Teva Pharmaceut..
11/27DJBIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
11/21 BIOGEN : Appoints Jeff Capello as Executive Vice President and Chief Financial O..
11/20 BIOGEN : to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
11/02 BIOGEN : Appoints Chirfi Guindo as Executive Vice President and Head of Global M..
11/02 BIOGEN : Earnings Review and Free Research Report: Biogen’s Adjusted EPS Surged ..
11/02 BIOGEN : Presents New Data from Long-Term Extension of Phase 1b Study of Investi..
More news
Sector news : Biopharmaceuticals
08:42aDJGLAXOSMITHKLINE : Encouraged By Blood-Cancer Drug Study
07:32aDJSANOFI : Receives U.S. FDA Approval for Insulin Injection Admelog
12:56a Monsanto offers cash to U.S. farmers who use controversial chemical
12/11 ASTRAZENECA : GSK's new pharma head on lookout for cancer deals to boost pipelin..
12/11DJSANOFI : Urges Philippines to Lift Dengue Vaccine Suspension -AFP
More sector news : Biopharmaceuticals
4-Traders Strategies on BIOGEN 
BIOGEN IDEC  - 2014
Back on a stimulating support
BUY
BIOGEN IDEC - 2013
The bullish trend is not over
BUY
More Strategies
News from SeekingAlpha
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
12/07 VALUATION DASHBOARD : Healthcare - Update
12/07 YOUR DAILY PHARMA SCOOP : Gilead's Potential, Celgene CAR-T Candidate, Cellectar..
12/06 Biotech drug pricing should not get substantially worse next year - Mizuho
12/05 Looking For Top Stocks In The Strongest Performing Sectors
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 358 $
Spread / Average Target 9,3%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alisha A. Alaimo Senior Vice President-US Therapeutic Operations
Gregory F. Covino VP-Finance, Chief Financial & Accounting Officer
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN22.28%69 371
CSL LIMITED40.81%48 247
ALEXION PHARMACEUTICALS-10.99%25 571
GRIFOLS SA29.24%17 782
BIOMARIN PHARMACEUTICAL-2.51%14 399
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%7 224